22,000 Shares in Krystal Biotech, Inc. $KRYS Purchased by Elmind Capital LP

Elmind Capital LP purchased a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 22,000 shares of the company’s stock, valued at approximately $5,424,000. Krystal Biotech makes up 1.6% of Elmind Capital LP’s investment portfolio, making the stock its 17th largest holding. Elmind Capital LP owned approximately 0.08% of Krystal Biotech at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Sound Income Strategies LLC boosted its stake in Krystal Biotech by 1,270.0% in the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares in the last quarter. Greenline Wealth Management LLC bought a new position in Krystal Biotech during the 4th quarter valued at about $34,000. Danske Bank A S bought a new position in Krystal Biotech during the 3rd quarter valued at about $35,000. UMB Bank n.a. lifted its stake in Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares during the period. Finally, Global Retirement Partners LLC lifted its stake in Krystal Biotech by 788.9% during the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after acquiring an additional 142 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Up 5.7%

NASDAQ KRYS opened at $341.66 on Thursday. Krystal Biotech, Inc. has a 12 month low of $127.99 and a 12 month high of $347.67. The stock has a market cap of $10.07 billion, a price-to-earnings ratio of 45.68 and a beta of 0.53. The company’s 50 day moving average is $292.56 and its two-hundred day moving average is $270.63.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The company had revenue of $116.36 million for the quarter, compared to analysts’ expectations of $112.11 million. Sell-side analysts forecast that Krystal Biotech, Inc. will post 7.83 EPS for the current year.

Insider Buying and Selling

In other Krystal Biotech news, EVP John Charles Thomas sold 642 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

KRYS has been the topic of several research analyst reports. Wolfe Research initiated coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They set a “peer perform” rating on the stock. Citigroup upped their target price on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Wall Street Zen upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings upgraded shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday. Finally, HC Wainwright upped their target price on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research note on Tuesday. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $329.78.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.